오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - paroxetine hydrochloride, quantity: 22.2 mg - tablet, film coated - excipient ingredients: mannitol; titanium dioxide; magnesium stearate; copovidone; colloidal anhydrous silica; microcrystalline cellulose; hypromellose; sodium starch glycollate; purified talc - paroxetine gh is indicated for the treatment of : - major depression and for the prevention of relapse of depressive symptoms - obsessive compulsive disorder (ocd) and prevention of relapse of ocd - panic disorder and for the prevention of relapse of panic disorder - social anxiety disorder/social phobia - general anxiety disorder - post-traumatic stress disorder.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - sertraline hydrochloride, quantity: 111.9 mg (equivalent: sertraline, qty 100 mg) - tablet, film coated - excipient ingredients: hyprolose; sodium starch glycollate type a; titanium dioxide; polysorbate 80; microcrystalline cellulose; calcium hydrogen phosphate; macrogol 400; hypromellose; magnesium stearate - children and adolescents sertraline hydrochloride is indicated for the treatment of children (aged 6 years of age and older) and adolescents with ocd.,adults sertraline hydrochloride is indicated for the treatment of: ? major depression, obsessive compulsive disorder (ocd) and panic disorder ? social phobia (social anxiety disorder) and the prevention of its relapse ? pre-menstrual dysphoric disorder (pmdd) as defined by dsm-iv criteria

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - sertraline hydrochloride, quantity: 111.9 mg (equivalent: sertraline, qty 100 mg) - tablet, film coated - excipient ingredients: hyprolose; sodium starch glycollate type a; titanium dioxide; polysorbate 80; microcrystalline cellulose; calcium hydrogen phosphate; macrogol 400; hypromellose; magnesium stearate - children and adolescents sertraline hydrochloride is indicated for the treatment of children (aged 6 years of age and older) and adolescents with ocd.,adults sertraline hydrochloride is indicated for the treatment of: ? major depression, obsessive compulsive disorder (ocd) and panic disorder ? social phobia (social anxiety disorder) and the prevention of its relapse ? pre-menstrual dysphoric disorder (pmdd) as defined by dsm-iv criteria

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - sertraline hydrochloride, quantity: 55.95 mg (equivalent: sertraline, qty 50 mg) - tablet, film coated - excipient ingredients: macrogol 400; titanium dioxide; microcrystalline cellulose; polysorbate 80; calcium hydrogen phosphate; magnesium stearate; sodium starch glycollate type a; hyprolose; hypromellose - children and adolescents sertraline hydrochloride is indicated for the treatment of children (aged 6 years of age and older) and adolescents with ocd.,adults sertraline hydrochloride is indicated for the treatment of: ? major depression, obsessive compulsive disorder (ocd) and panic disorder ? social phobia (social anxiety disorder) and the prevention of its relapse ? pre-menstrual dysphoric disorder (pmdd) as defined by dsm-iv criteria

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - sertraline hydrochloride, quantity: 55.95 mg (equivalent: sertraline, qty 50 mg) - tablet, film coated - excipient ingredients: macrogol 400; titanium dioxide; microcrystalline cellulose; polysorbate 80; calcium hydrogen phosphate; magnesium stearate; sodium starch glycollate type a; hyprolose; hypromellose - children and adolescents sertraline hydrochloride is indicated for the treatment of children (aged 6 years of age and older) and adolescents with ocd.,adults sertraline hydrochloride is indicated for the treatment of: ? major depression, obsessive compulsive disorder (ocd) and panic disorder ? social phobia (social anxiety disorder) and the prevention of its relapse ? pre-menstrual dysphoric disorder (pmdd) as defined by dsm-iv criteria

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

specialised therapeutics glio pty ltd - aminolevulinic acid hydrochloride, quantity: 1.5 g - oral liquid, powder for - excipient ingredients: - gliolan is indicated in adult patients for visualisation of malignant tissue during surgery for malignant gliomas that are glioblastoma multiforme (gbm) on preoperative imaging, and who are intended for resection of the tumour.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - methylphenidate hydrochloride, quantity: 10 mg - capsule, modified release - excipient ingredients: iron oxide yellow; iron oxide red; methacrylic acid copolymer; triethyl citrate; macrogol 6000; iron oxide black; purified talc; gelatin; ammonio methacrylate copolymer; titanium dioxide; maize starch; purified water; sucrose; propylene glycol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; ethanol absolute; potassium hydroxide - ritalin 10 tablets and ritalin la capsules are indicated for the treatment of adhd. ritalin 10 tablets are also indicated for the treatment of narcolepsy. attention-deficit hyperactivity disorder (adhd) adhd was previously known as attention-deficit disorder. other terms used to describe this behavioural syndrome include: minimal brain dysfunction in children, hyperkinetic child syndrome, minimal brain damage, minimal cerebral dysfunction, minor cerebral dysfunction and psycho-organic syndrome of children. ritalin 10 / ritalin la are indicatedas an integral part of a total treatment program for adhd that may include other measures (psychological, educational and social) for patients with this syndrome. stimulants are not intended for use in the patient who exhibits symptoms secondary to environmental factors and/or other primary psychiatric disorders, including psychosis. special diagnostic considerations for adhd in children: the aetiology of this syndrome is unknown and there is no single diagnostic test. adequate diagnosis requires the use, not only of medical, but also of psychological, educational and social resources. characteristics commonly reported include: chronic history of short attention span, distractibility, emotional lability, impulsivity, moderate to severe hyperactivity, minor neurological signs and an abnormal eeg. learning may or may not be impaired. the diagnosis must be based upon a complete history and evaluation of the child and not solely on the presence of one or more of these characteristics. drug treatment is not indicated for all children with this syndrome. stimulants are not intended for use in children who exhibit symptoms secondary to environmental factors (e.g. child abuse in particular) or primary psychiatric disorders. appropriate educational placement is essential and psychosocial intervention is generally necessary. when remedial measures alone are insufficient, the decision to prescribe stimulant medicine will depend upon the physician's assessment of the chronicity and severity of the child's symptoms. continuation of treatment in adolescent and special diagnostic considerations for adhd in adults: there is limited information to guide clinicians about how long older adolescents should continue to receive treatment with drugs for attention deficit hyperactivity disorder (adhd). the decision should be based on the extent to which symptoms of adhd and social functioning have improved to a point that medication is no longer needed. if older adolescents have been largely symptom-free for a year and are functioning well, a trial without medication is warranted. this should be undertaken at times of low stress such as during holidays or in a period when a school routine is well established. adhd needs to be considered in adults who present with longstanding symptoms suggestive of adhd (inattention, impulsivity, disorganisation) that appear to have started in childhood and are persisting into adult life. further, people with personality disorder and/or problems with drug use accompanied by a significant level of impulsivity and inattention should be referred for evaluation by a psychiatrist with the training and skills required to assess and treat adhd. this expertise is necessary due to the overlap of adhd symptoms with anxiety, mood and personality disorders. narcolepsy the symptoms include daytime sleepiness, inappropriate sleep episodes and rapidly occurring loss of voluntary muscle tone. ritalin 10 is effective for symptoms of sleepiness but not for loss of voluntary muscle tone.

미국 - 영어 - NLM (National Library of Medicine)

surpass chemical company, inc. - iodine (unii: 9679tc07x4) (iodine - unii:9679tc07x4) - iodine 0.0262 kg in 1 kg - directions: before milking, dip or spray the entire teat with this product. wipe teats dry after application using a single service towel to avoid milk contamination. immediately after milking, submerge entire teat up to the base of the udder in an undiluted solution of metz formula 58 iodine teat dip. allow to air dry. do not wipe.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

care pharmaceuticals pty ltd - paracetamol, quantity: 24 mg/ml; codeine phosphate hemihydrate, quantity: 1 mg/ml - oral liquid - excipient ingredients: macrogol 400; purified water; saccharin sodium; methyl hydroxybenzoate; glycerol; citric acid monohydrate; sodium citrate dihydrate; propyl hydroxybenzoate; sodium chloride; flavour - for the temporary relief of acute moderate pain when paracetamol alone is not sufficient in patients over the age of 12 years (see also contraindications and paediatric use).

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

reckitt benckiser pty ltd - ibuprofen, quantity: 200 mg; codeine phosphate hemihydrate, quantity: 12.8 mg - tablet, film coated - excipient ingredients: hypromellose; sodium starch glycollate; microcrystalline cellulose; purified talc; pregelatinised maize starch; titanium dioxide; purified water; industrial methylated spirit - for the temporary relief of acute moderate pain and inflammation in patients over the age of 12 years ( see also contraindications and paediatric use)